Companies / QSAM Biosciences, Inc.
QSAM Biosciences, Inc.
QSAMCIK 1310527
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jan 22, 2021 | Nelson Christopher M. Executive | Buy Open-market buy | Preferred Series B Stock | $400.0K | +20 | 20 | medium |
| Sep 30, 2020 | Whitney Scott W. Director | Other Derivative conversion | COMMON STOCK | $155.1K | +705K | 705,176 | low |
| Dec 17, 2020 | Bolin Kevin CEO | Grant Grant or award | COMMON STOCK | $153.1K | +696K +135.48% | 1,209,490 | low |
| Oct 26, 2020 | Nelson Christopher M. Executive | Grant Grant or award | COMMON STOCK | $93.2K | +424K +155.49% | 696,041 | low |
| Sep 30, 2020 | Mayersohn Joel David Director | Other Derivative conversion | COMMON STOCK | $73.0K | +332K +834.59% | 371,594 | low |
| Dec 19, 2023 | Checkmate Strategic Capital 2, LLC 10% owner | Other Derivative conversion | Common Stock | $45.0K | +9K +44.98% | 27,624 | low |
| Feb 6, 2024 | Nelson Christopher M. Executive | Other Derivative conversion | Common Stock | $26.0K | +9K +5.01% | 182,000 | low |
| Feb 6, 2024 | Nelson Christopher M. Executive | Other Derivative conversion | Common Stock | $26.0K | +9K +5.01% | 182,000 | low |